Women screened for cervical cancer in Sweden are currently treated under a one-size-fits-all programme, which has been successful in reducing the incidence of cervical cancer but does not use all of the participants' available medical information. This study aimed to use women's complete cervical screening histories to identify diagnostic patterns that may indicate an increased risk of developing cervical cancer. A nationwide case-control study was performed where cervical cancer screening data from 125,476 women with a maximum follow-up of 10 years were evaluated for patterns of SNOMED diagnoses. The cancer development risk was estimated for a number of different screening history patterns and expressed as Odds Ratios (OR), with a history of 4 benign cervical tests as reference, using logistic regression. The overall performance of the model was moderate (64% accuracy, 71% area under curve) with 61-62% of the study population showing no specific patterns associated with risk. However, predictions for high-risk groups as defined by screening history patterns were highly discriminatory with ORs ranging from 8 to 36. The model for computing risk performed consistently across different screening history lengths, and several patterns predicted cancer outcomes. The results show the presence of risk-increasing and risk-decreasing factors in the screening history. Thus it is feasible to identify subgroups based on their complete screening histories. Several high-risk subgroups identified might benefit from an increased screening density. Some low-risk subgroups identified could likely have a moderately reduced screening density without additional risk.
surgical intervention. Screening by HPV DNA testing 10 is starting to replace LBC as the standard for primary cervical screening, mainly due to increased sensitivity. 11 Cervical screening was introduced in Sweden in the 1960 s and the organised screening programme started in the 1970s. 12 The programme invites all female residents in Sweden aged 23-50 to a screening test every 3 years, and all aged 51-60 every 5 years. 13 In 2012, >90% of all women invited had participated in the programme at least once in the past 6 years. 14 The Swedish National Cervical Screening Registry (NKCx) collects all cervical screening records since 1969, including organised, opportunistic and histology tests. 15 Currently, most screening organisations, in Sweden and elsewhere, use only the results from the last prior screening test to determine when a woman should be recalled to screening. Women with many prior negative results are called with the same interval to screening as women with few negative results or a history of low grade abnormalities, despite the fact that the first group may be at significantly lower risk. This one-size-fits-all principle has been successful in reducing cervical cancer incidence, 16 but in the era of personalised medicine may be subject to improvement. This study aims to categorise women based on their entire screening history, as detailed in NKCx, into risk groups regarding their prospects of developing cervical cancer, which could serve as a basis for personalised recommendations regarding their screening recall interval.
Material and Methods

Data sources
The Swedish National Cervical Screening Registry (NKCx) has collected cervical screening test results since 1969, including organised, opportunistic and histology tests. 15 The counties started their complete records successively, and the registry is complete for all of Sweden since 1995. Cytological diagnoses in NKCx are classified according to the Systematised Nomenclature of Medicine (SNOMED) code system defined by the Swedish Association for Clinical Cytology.
Cancer diagnoses are recorded according to the International Statistical Classification of Diseases, Tenth Revision (ICD-10). 17 
Study population
The study population was an updated version of a nationwide audit dataset. 5 The screening histories of women participating in the study were drawn from the NKCx, with all 4,137 cervical cancer cases from 2002 to 2010 used as cases, and 121,339 age-matched controls identified from the National Population Registry (NPR). The dataset contained 29,665 case cervical tests and 678,482 control cervical tests. The ICD diagnoses considered were C53.0 (malignant tumour of the endocervix), C53.1 (malignant tumour of the exocervix) and C53.9 (malignant tumour in an unspecified location of the cervix uteri). From this audit set, all 147,075 cervical tests taken after the first cervical cancer diagnosis were excluded. Only the initial cancer diagnosis was included. For every test taken within two years of a prior test, the last of these was used. The other cervical tests were removed to ensure that duplicated diagnoses were not skewing the data in situations where retesting is frequent. All tests without a SNOMED code were excluded. All tests taken within six months of the cancer diagnosis were removed. All histories that appeared both in the control and the case set were removed from the control set. Any control cervical tests without a matched case at this point were removed (Fig. 1) .
Cervical biopsy data was also gathered from NKCx, for all participants recorded in the cytology data. This provided biopsy data for 4,095 cases and 42,814 controls. Instead of using the biopsy diagnosis data directly, the severity of the worst diagnosis was used on the assumption that only one cancer case was covered (i.e., no recurrence) for each participant. The following data were excluded: any test without a sample date, all tests taken after the cancer diagnosis date (the matched case date for controls), any biopsies for controls that also appeared as cases (the case data was retained), all tests appearing within 6 months of the cancer diagnosis (the matched case date for controls), and all tests taken within 6 months of another test (the most severe diagnosis in these was kept). Finally, all tests pertaining to an unmatched control or case were removed. The end result of the biopsy data was a single parameter for each history to represent the category of the most severe biopsy result from that history (Fig. 2) .
Definitions of exposures
Each screening test diagnosis according to the SNOMED nomenclature was considered as an exposure. In addition, the following types of derived exposures were computed for the participants:
What's new? Data gathered during cervical-cancer screening programmes have often been used for epidemiological studies, but not for machine-learning-based risk prediction. In this study, the authors constructed a transparent, rule-based system to analyse the complete screening history of each participant, in order to identify diagnostic patterns that may indicate an increased risk of developing cervical cancer. High-risk subgroups might benefit from an increased screening frequency. This approach could thus enable personalised screening schedules based on estimated risk as determined by the algorithm.
Missed screening. The screening history of the individual was read backwards from the cancer diagnosis. The date of the most recent screen preceding the cancer diagnosis was compared to the date of the cancer diagnosis event and if the difference was greater than twice the recommended screening interval, a "missed screening" entry was added between the compared dates. The entry was added one recommended screening interval before the cancer diagnosis event. If the difference was more than three times the recommended screening interval, a second missed screening was added in a similar fashion, at two recommended screening intervals before the cancer diagnosis event. If needed, third and fourth missed screens and so forth were added according to the same method.
Years since recommended screening schedule. In addition to "missed screening" entries, a parameter measuring the total time (in years) that had passed for all screening intervals in excess of the recommended screening schedule was estimated. This value increased for each interval where >3 years had passed after a screening event (or 5 years if the individual was over 50 years of age). In histories with Current number of "missed screening" entries. This parameter gave the number of contiguous "missed screening" entries up until the point of cancer diagnosis. Only the last sequence of missed entries was measured in this variable as the risk from missing screens was significantly reduced once a new test was taken. This was needed since a sequence of "missed screening" entries in the middle of the history was shown to entail no increased risk of cancer, most likely as it had been negated by more recent screens.
Current number of benign screening diagnoses. This parameter shows the current number of contiguous benign screening diagnoses.
Cumulative risk score. To represent the temporality of diagnoses and the risk associated with each, a CRS was calculated as a function of the diagnosis sequence, where SNOMED diagnoses were given a score according to severity and weighted by time since diagnosis (see below). 
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Total number of screening events. A parameter for showing the total number of events in a history, including "missed screening" entries. This parameter did not include screening events that had been excluded.
Most severe biopsy result. A parameter showing the most severe biopsy diagnosis according to the SNOMED nomenclature that the person had ever received (indexed by category of severity).
Analysis
Analysis was performed with SAS software 18 (9.3/9.4). Datasets were generated from the study base. All cases of cervical cancer with at least 4 and at most 10 tests were selected from the source population. A random control with a matching number of screening tests was sampled for each case used. The final analysis datasets contained 1,658 cases with C53.9, 67 cases with C53.1, 46 cases with C53.0 and 1,771 controls (3,542 women in total). The sets were then fitted with required metadata for evaluation and rule generation via the bioinformatics tool ROSETTA 19 (see Supporting Information for details). These evaluations provided sensitivity, specificity and ROC data to describe the overall performance level for the classifier and the dataset. The rules on which the classifier was built identified particular screening result patterns and how well they could discern between case and control histories. The subgroups of women in the data that could be discerned by these patterns were then evaluated for risk of cervical cancer compared to the baseline risk in women with four cervical tests, all of which were recorded as benign, from the entire study base. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed for several levels of severity to show trends in both subgroup size and estimated risk. When a relevant rule was found, the ORs were also recalculated using the entire population, not merely those in the tested dataset.
The classifier built was then tested in a 10-fold cross-validation for accuracy, sensitivity and specificity. The false discovery rate (FDR) was also tested to give the receiver operating characteristics (ROC) curve for the classifier, which details the relation between specificity and sensitivity, and the performance of the model was measured as the area under the curve (AUC) of this ROC curve. The overall performance of the classifier was computed as the average of all cross-validations.
The pipeline for constructing a dataset followed by evaluation and analysis was used to test the discerning power of derived features such as time between cervical tests, remaining risk from last high-risk cervical test and others. To avoid overfitting on singular datasets the evaluation of derived features was performed on multiple datasets with different sampled controls. If these features appeared in the ruleset of the classifier while the overall performance increased they were retained in later iterations.
To construct the CRS, the screening histories were first given a preliminary risk estimate score representing previous screening diagnoses to determine how seriously an ambiguous diagnosis should be handled. This scoring algorithm was constructed iteratively such that the score numbers for each SNOMED diagnosis were adjusted to separate the controls from the cases to the greatest extent. The measurement for this overlap of cases and controls was the number of cases multiplied by the number of controls at each encountered score, with the final score divided by the dataset size (see Supporting Information).
As the CRS was based on cervical test diagnoses from a screening programme, it was not linearly correlated over the datasets, but corresponded only to the combinatorial scores available from the datasets given the scoring matrix used.The CRS values were weighted with an inverse distance from the cancer diagnosis such that the most recent event would have the most impactful weight (see Supporting Information).
The weight was the maximum (100%) for the three years immediately preceding the cancer diagnosis, and then declined rapidly going back in time, to even out after twelve years (Fig. 3 ).
The CRS was categorised with cut-points at 23, 21, 1, 9 and 20 to provide intervals that were both of sufficient size to result in meaningful prediction and to provide coverage for screening histories with similar risk profiles.
Results
Of all the participants, 64.0% were predicted correctly as cases or controls. This can be compared to a random assignment where an accuracy of 50% is expected. The model had an AUC of 71.0% (data not shown). The largest group identified, 61.2% of the controls and 62.1% of the cases, showed no specific patterns of previous screening history associated with risk; this was consistent with a value of the cumulative risk score (CRS) in the range [-1, 0] (Fig. 4) . Exclusion of this group from the dataset increased predictive success of the model to 73.6% and the AUC of the model to 75.6% (data not shown).
Greater predictive accuracy of the CRS was found for risk patterns in subgroups of participants. The vast majority (98%) of controls had at most a value of 10 in CRS, whereas a CRS in the range of 10-40 was substantially more common among cases (11%, Fig. 4 The variable "Current number of benign screening diagnoses" counted the number of uninterrupted benign diagnoses in a row from the last time of diagnosis. This held little predictive power on its own. At 31 the OR was 1.0 (0.8-1.2) with 557 cases and 25,087 controls. At 61 the OR was 0.9 (0.8-1.2) with 220 cases and 10,391 controls. Similarly, using the variable "Total number of screening events in the history" on its own did not result in any useful risk stratification of participants. At 41 screens the OR was 1.8 (1.5-2.1) with 1,628 cases and 41,232 controls. At 61 screens the OR was 1.6 (1.3-1.9) with 739 cases and 20,839 controls.
Several combinations of variables were explored, but mostly resulted in too few observations. The combination of variables CIN1 (SNOMED code M74006) and "Current number of benign screening diagnoses" resulted in high ORs. Individually, the benign diagnosis variable had an OR of 2.7 for < 4, 2.9 for < 3 and 3.5 for < 2. M74006 > 0 had an OR of 5.1. With the combination of M74006 > 0 and benign diagnoses < 2 the OR was 12.1 (9.0-16.3) with 225 cases and 6,703 controls. Setting the limit benign diagnoses < 3 while retaining M74006 > 0 leads to an OR of 8.5 (6.4-11.3) with 230 cases and 6,857 controls. Relaxing the limit further to benign diagnoses < 4 while retaining M74006 > 0 led to an OR of 6.5 (4.9-8.5) with 235 cases and 7,036 controls.
Finally, we investigated risk associated with the participants "Most severe biopsy result" (Supporting Information Table 3 ). The worst diagnosis (Adenocarcinoma in situ) had an OR of 94.7 (64.1-139.9) for subsequent cervical cancer, while category 51 (CIN2/CIN3/AIS) had an OR of 13.4 (10.2-17.6), category 31 (atypical sample or worse) an OR of 8.1 (6.3-10.3) and 11 (any assessable result) an OR of 4.3 (3.5-5.3). The subgroups consisted of 146 cases and 88 controls for category 7, 171 cases and 806 controls for category 51, 253 cases and 1,642 controls for category 31, and 237 cases and 2,485 controls for category 11.
We performed several sensitivity analyses to test the robustness of the results. To measure the reliability of the CRS measurement for different history-lengths, as the screening histories ranged from 4 to 10 examinations each, the ORs and mean standard deviation for this score was computed using different cutoffs for the length of the individual histories. Each history was truncated at a set of cutoff points: at Fig. 5 ). ORs were overall stable across history lengths, except for slight alterations at the 15 year cut point and some variation in point estimates for higher CRS values accumulated over a short period only, that is, 10 years, where data was sparse (Table 1) . Likewise, when inspecting the corresponding mean values of OR standard deviations for different history lengths, these were generally stable across cutoff points indicating stability of the model regardless of history length (data not shown).
Discussion
We here present a novel way of simultaneously considering the entire screening history of a woman when estimating her risk of cervical cancer. To our knowledge, this represents the most comprehensive assessment to date of such an approach. Whereas the overall model was of modest discriminatory performance, the success in identifying specific subgroups of high-risk women is more promising: the highest risk group as identified by the CRS accounted for almost 10% of the total number of cancer cases over a period of 10 years. Potentially, these data and similar could be used for the design of adapted screening intervals according to each individual's risk group for cancer. It should be emphasised that the predictive abilities reported are likely to be of insufficient strength for clinical management of patients. Rather the algorithm could be used by screening programmes to adjust screening intervals for the very high risk subgroups that we have identified.
It should be noted that 66% of case-cervical tests and 52% of control-cervical tests from the initial dataset were filtered before the analysis. Those correspond to 373,276 cervical tests and derived largely from our three different filters removing diagnostic cervical tests, postdiagnostic cervical tests and cervical tests clustered-within-a-two-year-timeframe. However, removing diagnostic and postdiagnostic cervical tests puts the model in the same place as the clinicians with the same access to information, and reflects the data available when a prediction must be made. Filtering these cervical tests thus removes any "hindsight" of the model, ensuring that predictions are made on the same basis as in actual screening practices. Furthermore, redundancy of information from multiple cervical tests in a short timeframe can lead to weighting and pattern issues as ten negative cervical tests over 30 years is not the same as ten negative cervical tests over ten days. The latter is only verifying a previous diagnosis while the former is an informative sequence of ten disparate diagnoses. Removing all but one diagnosis in such a cluster removes unnecessary repeats and prevents patterns from disappearing. Only the latest diagnosis is retained, simulating the conclusion drawn by the responsible clinician. Whether the last diagnosis is the correct one or not is of little import; the purpose of the filter is to mimic the conditions of clinical practise, not to select the most accurate diagnosis.
A limitation of the study is that we used a somewhat restricted population of women with 4-10 screening tests. However, this is not as restrictive an approach as it may appear. In order to gain significant advantages over the established model, we need approximately 4 visits to generate histories of such a length that the variation in these can be explored. Several rules identified in this subset of women can be transferred back to the full population, even if they do not have 4 tests recorded. Furthermore, histories of >10 tests tend to come from women who are quite atypical compared to the majority of the screening population. A history of >10 tests represents on average a follow-up of over 30 years, or intense periods of clinical work-up. Neither of these are representative of the majority of women participating in screening. We also excluded women with closely spaced visits since The time limits (25-10 years) specify different cut-offs for including data in the CRS calculations, that is, the 15 years column uses only diagnoses that were taken in the last 15 years. The OR estimates the risk for cervical cancer.
these are mainly linked to diagnostic work-up of the same diagnostic case, and can be said to mostly be a reaffirmation of the same diagnosis multiple times. Therefore, such visits do not contribute to our algorithm per se, and skew the calculation of our cumulative risk score. We demonstrate the use of a CRS which is in principle straightforward to calculate for each woman participating in a screening programme with available records. Earlier versions of the CRS values depended on "total number of events" in the ruleset, as the risk associated with a diagnosis was dependent on how long ago the cervical test was taken. This was tested by censoring the dataset based on time from cancer diagnosis. Only the cervical tests that were taken within a 15 year period prior to the cancer diagnosis were kept, and ORs were calculated for various levels of the CRS. The results showed that a high CRS within the past 15 years had a stronger connection to the outcome than a high CRS without any time restraint. To reduce this score inconsistency, the model was reworked to take time into account when computing the score. Without weighting, the OR for long histories would be expected to increase at low risk scores and decrease at high risk scores when compared to short histories. This is because a CRS of 0 after six cervical tests means that at least one result was not benign (six benign results would give a CRS close to 25), where as a CRS of 0 after one cervical test requires a benign result. Inversely, a CRS of 30 after 25 years of screening could well refer to the two first cervical tests in that history which are no longer risk factors, while a CRS of 30 after 10 years of screening means that at least 66% of the screening history contains diagnoses considered conducive to cancer development. The results (Fig. 5) confirmed that recent diagnoses strongly correlated with cancer development are the most serious indicators, and further showed the negative, or "protective," prediction values of benign cervical tests evening out slowly from 20 years onward.
The limited reduction in risk from contiguous benign screening results, indicating that women with several previous normal cervical tests are still at risk for cervical cancer, suggest that any prognostic value that may influence the screening participants is limited by the performance of cytological screening. This prevents a more comprehensive and determined reduction in screening density for low-risk participants. These results align with previous studies showing limited protective effects from contiguous benign cervical tests. 20 In contrast, consistent with other studies, 21 the variable "time since the last screening event" could successfully be used to estimate cancer risk.
While the results of screening may have some riskreducing effects from biopsy samples and excisions, it is not a protective but pro-active effort. Tumours will develop whether they are discovered early or not. As such the successful outcome of screening is not the prevention of tumours but the discovery of pre-malignant or in situ dysplasia (CIN2, CIN3/CIS, HSIL). 22 It is possible that in this study the discovery of such dysplasia via screening confounds the predictive model as the pattern is consistent with carcinogenesis but the development is halted in a pre-cancer phase. Going through the histories that include dysplasia and separating them by remedial actions (if any) could provide an answer to this possible confounding factor. 
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In addition to internal cross-validation of datasets, we also checked the validity of our model by comparing our risk estimates to those performed by others using standard logistic regression analysis in the original source audit dataset. Comparing our estimates of risk deriving from two-test histories with no-test histories during the last 8 years replicated the results found by Andrae et al. 23 These validations suggest that the dataset construction process is valid for the tests performed.
Finally, we note that while the use of the biopsy history was the strongest indicator for cancer, the late disease stage at which the information is gathered should typically render it less useful for predictive models. There is little to gain from using biopsy data in the model that would not already be known by the relevant personnel at that stage and predictive models should focus on the tools for primary screening of the included women. The strongest assessment is also the strongest predictor, as one would expect. The high cancer risk after a biopsy with adenocarcinoma in situ may reflect the difficulties in providing adequate treatment for these women. Additional features to classify by are needed in order to properly assess the risk of cytology-asymptomatic women, with detailed HPV status and social markers as likely candidates. Future studies are likely to contain such information as HPV screening is being deployed in many European countries after successful trials. 11 As praxis and diagnostic data advance the model will incorporate new or improved factors for a likely increase in predictive power.
We note that the potential application of personalised screening schedules must be balanced against the complexity of adding this practise to the intended screening system. Organised screening of the one-size-fits-all category has certainly been successful so far in reducing cervical cancer incidence, yet it should be noted that cervical cancer incidence is once again on the rise in Sweden 24 and it may be that we are approaching the limit of what the current programme can achieve in terms of disease prevention. In this context, the proposed algorithm may represent an improved way forward. National screening programmes that combine comprehensive records of previous diagnostic data with an automated system for invitations and recalls have infrastructure in place that could be well suited for integrating this kind of algorithm. However, less comprehensive screening programmes do not necessarily have the diagnosis histories needed for generating a robust implementation. This also relies on the algorithm being tested in the exact setting where use is contemplated before deployment, to ensure that the stratifications are sound and practical in each potential new programme situation. The risk group stratification levels used would also be modifiable by each respective organisation, so that each programme can decide what constitutes relevant risk groups.
The success in identifying high-or low-risk subgroups could be of substantial assistance when screening for cervical cancer in large populations. An increase in screening density for selected high-risk groups could be an efficient use of screening resources and might lead to increased pre-cancer discoveries, while a small reduction in screening density for low-risk groups could free resources. However, the current overall accuracy of the model is inadequate. The ongoing development and deployment of screening by HPV-test is expected to reduce cervical cancer incidence rates further 11 while producing additional screening data. The methodology described in this paper has been designed with the future availability of HPV-based screening data in mind and can be applied to such information, either replacing or supplementing the cytology data that was used here. Even if screening switches to HPV-based screening, the previous diagnostic history of cytological screening will continue to have a substantial predictive value also in the long term, arguing that the results from this method are likely to be useful for a considerable time even if the screening test is changed. After such a switch to HPV-based screening, substantial risk-predictive information can be obtained in terms of which tests have been done and the exact results (e.g., which HPV types have been detected). The approach studied here, capable of considering various combinations of previous test results, is easily extendible to such results and could thus be of significant value.
Future studies should also focus on demonstrating whether a relation between risk-group-specific ORs and screening density could be defined, and whether in that case a personalised screening interval for each individual could be designed.
